However, the tumor response rate to crizotinib in the ALK‐rearranged cohort was also lower in the anticoagulation subgroup than in the non‐anticoagulated subgroup, and a similar trend was also observed in the cohort of ROS1‐rearranged NSCLC. This evidence concerns the gene ROS1 and neoplasm.